User:Visionary3/sandbox

Ganda earned his MBBS from **Sawai Man Singh Medical College**, Jaipur, in 1966, followed by an MD in medicine at the **All India Institute of Medical Sciences**, New Delhi, in 1970.{{cite news |title=Meet Dr. Om Ganda: Medical Director of the Lipid Clinic at Joslin Diabetes Center and Recipient of the 2019 New England Choice Awards |url=https://inemultimedia.com/2019/11/meet-dr-om-ganda-medical-director-of-the-lipid-clinic-at-joslin-diabetes-center-and-recipient-of-the-2019-new-england-choice-awards-as-healthcare-pioneer/ |work=INE Multimedia |date=10 November 2019}}

He moved to Boston in 1971 for a research fellowship at Joslin and Harvard, completing additional endocrinology training at the **Boston VA Hospital** and **Peter Bent Brigham Hospital**.{{cite web |title=Harvard Catalyst profile: Om Ganda |url=https://connects.catalyst.harvard.edu/Profiles/profile/1258927 |access‑date=16 April 2025}}

Ganda joined Joslin’s faculty in 1973 and later became Medical Director of Lipid Clinic, Chair of the Clinical Oversight Committee, and Chair of Joslin Clinician Philanthropy Council.{{cite news |title=Dr. Om Ganda Appointed Chair of Joslin Clinician Philanthropy Council |url=https://indianewengland.com/dr-om-ganda-appointed-chair-joslin-clinician-philanthropy-council/ |work=India New England News |date=3 April 2017}} He has served on expert panels for the American Diabetes Association and the National Cholesterol Education Program, and teaches medicine at Harvard Medical School.

From 2012 to 2015, Ganda served as a commissioner on the Asian American Commission of the Commonwealth of Massachusetts, a statewide body that advocates on behalf of Asian American residents.{{cite web |title=Asian American Commission – 2014 Annual Report |url=https://www.mass.gov/doc/asian-american-commission-2014-annual-report/download |publisher=Commonwealth of Massachusetts |date=2015 |access-date=17 April 2025}}{{cite web |title=Faculty profile: Om Ganda |url=https://www.bestofidfindia.org/kolkata/faculty |website=Best of IDF India |access-date=17 April 2025}}

Over four decades, Ganda has been a co‑investigator on several landmark multicentre trials, including the **Diabetes Control and Complications Trial (DCCT/EDIC)**, the **Diabetes Prevention Program (DPP)**, and large cardiovascular‑outcome studies such as **REDUCE‑IT** and **PROMINENT**. He has authored more than 200 peer‑reviewed papers and 30 book chapters.

• **Master of the American Association of Clinical Endocrinology (MACE)**, 2023.
• **Healthcare Pioneer**, New England Choice Awards, 2019.

{{refbegin}}

• Ganda OP, et al. “Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.” N Engl J Med (2022).

• Ganda OP, et al. “Statins Tied to Diabetes Progression in Long‑Term Cohort.” Diabetes Care (2019).

• Ganda OP. Triglyceride‑rich lipoproteins, remnant‑cholesterol, and atherosclerotic cardiovascular disease. Current Opinion in Lipidology 34 (3): 105–113 (2023). doi:10.1097/MOL.0000000000000875.{{cite journal |last=Ganda |first=Om P. |title=Triglyceride‑rich lipoproteins, remnant‑cholesterol, and atherosclerotic cardiovascular disease |journal=Curr Opin Lipidol |volume=34 |issue=3 |pages=105–113 |year=2023 |doi=10.1097/MOL.0000000000000875}} :contentReference[oaicite:0]{index=0}

• Ganda OP. When to lower triglycerides? Current Opinion in Lipidology 31 (4): 238–245 (2020). doi:10.1097/MOL.0000000000000701.{{cite journal |last=Ganda |first=Om P. |title=When to lower triglycerides? |journal=Curr Opin Lipidol |volume=31 |issue=4 |pages=238–245 |year=2020 |doi=10.1097/MOL.0000000000000701}} :contentReference[oaicite:1]{index=1}

• Ganda OP. Beyond Statins: Who and When to Prescribe? Current Diabetes Reports 18 (11): 126 (2018). doi:10.1007/s11892‑018‑1087‑0.{{cite journal |last=Ganda |first=Om P. |title=Beyond Statins: Who and When to Prescribe? |journal=Curr Diab Rep |volume=18 |issue=11 |pages=126 |year=2018 |doi=10.1007/s11892-018-1087-0}} :contentReference[oaicite:2]{index=2}

• Ganda OP. Statin‑induced diabetes: incidence, mechanisms, and implications. F1000Research 5: 1499 (2016). doi:10.12688/f1000research.8976.1.{{cite journal |last=Ganda |first=Om P. |title=Statin‑induced diabetes: incidence, mechanisms, and implications |journal=F1000Res |volume=5 |pages=1499 |year=2016 |doi=10.12688/f1000research.8976.1}} :contentReference[oaicite:3]{index=3}

• Toth PP, Nelson JR, Soran H, Ganda OP, et al. Cross‑sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl. Frontiers in Cardiovascular Medicine 12: 1411233 (2025). doi:10.3389/fcvm.2025.1411233.{{cite journal |last1=Toth |first1=Peter P. |last2=Nelson |first2=John R. |last3=Soran |first3=Handrean |last4=Ganda |first4=Om P. |title=Cross‑sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl |journal=Front Cardiovasc Med |volume=12 |pages=1411233 |year=2025 |doi=10.3389/fcvm.2025.1411233}} :contentReference[oaicite:4]{index=4}

• Nelson JR, Hansen RA, Soran H, Ganda OP, et al. Comparison of product label vs real‑world safety data from branded icosapent ethyl users: a MarketScan analysis. Journal of Clinical Lipidology 19 (2): e126‑e134 (2025). doi:10.1016/j.jacl.2025.01.006.{{cite journal |last1=Nelson |first1=John R. |last2=Hansen |first2=Richard A. |last3=Soran |first3=Handrean |last4=Ganda |first4=Om P. |title=Comparison of product label vs real‑world safety data from branded icosapent ethyl users: a MarketScan analysis |journal=J Clin Lipidol |volume=19 |issue=2 |pages=e126–e134 |year=2025 |doi=10.1016/j.jacl.2025.01.006}} :contentReference[oaicite:5]{index=5}

• Warden BA, Miles JR, Oleaga C, Ganda OP, et al. Unusual responses to PCSK9 inhibitors in a real‑world clinical cohort. American Journal of Preventive Cardiology 1: 100012 (2020). doi:10.1016/j.ajpc.2020.100012.{{cite journal |last1=Warden |first1=Bruce A. |last2=Miles |first2=Joshua R. |last3=Oleaga |first3=Carlota |last4=Ganda |first4=Om P. |title=Unusual responses to PCSK9 inhibitors in a real‑world clinical cohort |journal=Am J Prev Cardiol |volume=1 |pages=100012 |year=2020 |doi=10.1016/j.ajpc.2020.100012}} :contentReference[oaicite:6]{index=6}

• Ganda OP, Mitri J, et al. Current consensus and controversies in guidelines for lipid and hypertension management in diabetes. Diabetes Therapy 7 (4): 713‑730 (2016). doi:10.1007/s13300‑016‑0210‑5.{{cite journal |last=Ganda |first=Om P. |title=Current consensus and controversies in guidelines for lipid and hypertension management in diabetes |journal=Diabetes Ther |volume=7 |issue=4 |pages=713‑730 |year=2016 |doi=10.1007/s13300-016-0210-5}} :contentReference[oaicite:7]{index=7}

{{refend}}

• [https://joslin.org/find-an-expert/om-ganda-md Official profile – Joslin Diabetes Center]

{{Authority control}}

{{Draft categories|

:Category:American endocrinologists}}

{{Draft categories|

:Category:Harvard Medical School faculty}}

{{Draft categories|

:Category:Indian emigrants to the United States}}

{{Draft categories|

:Category:Living people}}

{{Draft categories|

:Category:Year of birth 1945 (living people)}}